FindTrial
Sign In

A Retrospective Study on the Efficacy and Safety of a Simplified Etoposide Regimen for Macrophage Activation Syndrome

Efficacy and Safety of a Simplified Etoposide Protocol for Macrophage Activation Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106984
Enrollment
Unknown
Registered
2025-08-01
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macrophage Activation Syndrome

Interventions

Modified treatment group:None
Standard treatment group:None

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients who visited our hospital, aged between 14 and 80 years. 2.According to the HLH-2004 diagnostic criteria, patients diagnosed with macrophage activation syndrome. 3.Received etoposide treatment.

Exclusion criteria

Exclusion criteria: 1.Individuals excluded based on the inclusion criteria 2.Patients diagnosed with tumors within 6 months prior to the initiation of this study 3.Any other condition for which the investigator deems the patient unsuitable to participate in this trial (including but not limited to administrative reasons)

Design outcomes

Primary

MeasureTime frame
Complete blood count;—

Countries

China

Contacts

Public ContactJixin Zhong

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

zhongjixin620@163.com+86 181 5441 2011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026